| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 10.00 Billion |
| Market Size (2030) | USD 13.90 Billion |
| CAGR (2025 - 2030) | 6.81 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Diagnostic Radiopharmaceuticals and Contrast Media Market Analysis
The Global Diagnostic Radiopharmaceuticals and Contrast Media Market size is estimated at USD 10.00 billion in 2025, and is expected to reach USD 13.90 billion by 2030, at a CAGR of 6.81% during the forecast period (2025-2030).
The diagnostic imaging industry continues to evolve rapidly, driven by increasing healthcare expenditure and the growing adoption of advanced medical imaging technologies across healthcare facilities worldwide. The integration of artificial intelligence and machine learning capabilities into imaging systems is revolutionizing diagnostic accuracy and workflow efficiency. This transformation is particularly evident in the development of AI-enabled automated radiology platforms, which are fundamentally changing how interventional radiology procedures are conducted. The convergence of these technologies with traditional imaging modalities is creating new opportunities for enhanced diagnostic precision and improved patient outcomes.
The industry is witnessing a significant shift toward precision medicine and personalized diagnostics, with an increasing focus on developing targeted imaging agents and contrast media. According to projections from the International Agency for Research on Cancer (IARC), the global burden of cancer is expected to reach 27.5 million new cases by 2040, highlighting the critical need for advanced diagnostic solutions. This growing disease burden has catalyzed research and development efforts in novel radiopharmaceuticals and contrast agents, particularly those offering enhanced specificity and reduced side effects. The market is seeing increased investment in research and development of new radioisotopes and medical imaging agents that can provide more detailed and accurate diagnostic information.
The regulatory landscape is evolving to accommodate innovative technologies while ensuring patient safety, with authorities increasingly focusing on streamlining approval processes for novel diagnostic agents. Notable regulatory milestones include the FDA clearance granted to Vect-Horus and RadioMedix in July 2021 for evaluating 68Ga-RMX-VH in glioblastoma multiforme detection. This regulatory evolution is accompanied by increasing collaboration between industry players, research institutions, and regulatory bodies to establish standardized protocols for new imaging technologies and contrast media. The industry is also seeing a rise in strategic partnerships aimed at developing next-generation diagnostic solutions.
The market is experiencing a notable trend toward the development of hybrid imaging systems and multimodal molecular imaging agents that can provide complementary diagnostic information. Manufacturers are increasingly focusing on developing systems that offer improved resolution, reduced radiation exposure, and enhanced diagnostic capabilities. This trend is exemplified by significant product launches such as GE Healthcare's introduction of the StarGuide SPECT/CT system, designed to advance precision health and theranostics. The industry is also witnessing growing interest in developing contrast agents that are compatible with multiple imaging modalities, offering greater flexibility and diagnostic accuracy while potentially reducing the need for multiple diagnostic procedures.
Diagnostic Radiopharmaceuticals and Contrast Media Market Trends
Technology Advancements in Medical Imaging
The technological landscape of medical imaging has undergone significant transformation with the advancement of nuclear medicine technologies and diagnostic capabilities. According to the World Nuclear Association, nuclear medicine has revolutionized diagnostic procedures, particularly through single photon emission computerized tomography (SPECT) and positron emission tomography (PET), which offer precise and sophisticated diagnostic capabilities. These technologies have enabled healthcare providers to obtain detailed diagnostic information about specific organ functioning and have become instrumental in both the diagnosis and therapy of various medical conditions. The integration of artificial intelligence in developing advanced imaging systems has further enhanced the capabilities of diagnostic imaging, with studies showing impressive accuracy and sensitivity in identifying imaging abnormalities.
The continuous innovation in contrast media and imaging modalities has led to significant improvements in diagnostic accuracy. For instance, in 2023, researchers at Rice University made breakthrough developments in gadolinium-based medical imaging contrast agents, the gold standard in magnetic resonance imaging (MRI), enhancing their effectiveness and safety profile. Additionally, the emergence of automated, AI-driven algorithms has revolutionized image acquisition in radiology, as evidenced by collaborations between companies like Subtle Medical and Bayer, which are exploring opportunities to utilize artificial intelligence to enhance image quality and expand contrast media applications. These technological advancements have not only improved diagnostic accuracy but have also reduced radiation exposure and enhanced patient comfort during imaging procedures.
Understand The Key Trends Shaping This Market
Download PDF
Increasing Demand for Image-Guided Procedures and Diagnostics
The rising prevalence of complex medical conditions has catalyzed the demand for image-guided procedures and diagnostics, particularly in neurosurgery, orthopedic surgery, and urology. Image-guided surgery (IGS) has emerged as a crucial advancement that enables surgeons to use tracked surgical instruments in conjunction with preoperative or intraoperative images for precise procedural guidance. According to the International Society of Nephrology (ISN), approximately 850 million people globally are affected by kidney illness, with one in ten people suffering from chronic kidney disease (CKD). This significant patient population has driven the demand for advanced imaging techniques for accurate diagnosis and treatment planning.
The field has witnessed remarkable progress in functional molecular imaging, particularly in nephro-urology applications. PET-based molecular imaging of the kidneys, though still in its early stages, has shown promising results in providing precise and thorough evaluation of renal radiotracer urodynamics. Recent developments in radiopharmaceuticals and imaging agents have further enhanced the capabilities of image-guided procedures. For instance, studies have demonstrated that PVA-modified Gd2O3:Eu nanoparticles combined with 18F-FDG have significantly improved intraoperative tumor detection with high imaging contrast, marking a significant advancement in image-guided surgery applications.
High Prevalence of Cancers and Cardiac Diseases
The global healthcare landscape continues to be significantly impacted by the rising prevalence of cancer and cardiovascular diseases, creating an increased demand for advanced diagnostic imaging solutions. According to the World Health Organization, cardiovascular diseases remain the leading cause of death globally, with an estimated 17.9 million people dying from CVDs annually, representing 32% of all global deaths. The British Heart Foundation statistics indicate that approximately 7.4 million people are living with heart and circulatory diseases in the United Kingdom, highlighting the significant burden of cardiac conditions in developed nations.
The cancer burden continues to grow globally, with recent statistics from GLOBOCAN indicating breast cancer as the leading cause of cancer-related deaths worldwide. The development of receptor-targeted image-guided Radionuclide Therapy (TRT) has emerged as a promising approach to cancer treatment, particularly in the field of alpha-particle therapy. Recent preclinical and clinical studies have demonstrated significant progress in radiopharmaceutical theranostic therapies for cancer, with the 203Pb/212Pb theranostic pair showing particular promise for future applications. These developments in diagnostic nuclear medicine and therapeutic capabilities have been crucial in addressing the growing burden of both cancer and cardiovascular diseases, enabling earlier detection and more effective treatment planning.
Segment Analysis: Radiopharmaceuticals
SPECT Segment in Global Diagnostic Radiopharmaceuticals Market
Single Photon Emission Computed Tomography (SPECT) dominates the global diagnostic radiopharmaceuticals market, commanding approximately 60% of the market share in 2024. This significant market position is primarily driven by the widespread adoption of SPECT imaging in various medical applications, particularly in cardiology, neurology, and thyroid imaging. The segment's dominance is reinforced by the extensive use of key radioisotopes like Technetium-99m (Tc-99m), which accounts for the majority of SPECT procedures globally. The versatility of SPECT imaging in providing detailed functional information about organs and tissues, combined with its cost-effectiveness compared to other imaging modalities, continues to drive its widespread adoption in healthcare facilities worldwide. The segment's robust performance is further supported by the increasing prevalence of cardiovascular diseases and neurological disorders, which require regular diagnostic imaging for effective patient management.
PET Segment in Global Diagnostic Radiopharmaceuticals Market
The Positron Emission Tomography (PET) segment is emerging as the fastest-growing segment in the diagnostic radiopharmaceuticals market, projected to grow at approximately 5% CAGR from 2024 to 2029. This accelerated growth is primarily attributed to technological advancements in PET imaging systems and the increasing adoption of hybrid imaging technologies like PET/CT and PET/MRI. The segment's growth is further fueled by the rising demand for precise diagnostic tools in oncology, where PET imaging plays a crucial role in cancer staging and treatment monitoring. The development of novel PET radiopharmaceuticals and their expanding applications in neurology and cardiology are also contributing to this segment's rapid growth. Additionally, the increasing investment in healthcare infrastructure and the growing awareness about the benefits of early disease detection using PET imaging are driving the segment's expansion in both developed and emerging markets.
Segment Analysis: Contrast Media
Iodinated Contrast Media Segment in Diagnostic Radiopharmaceuticals and Contrast Media Market
Iodinated contrast media dominates the contrast media market, commanding approximately 45% market share in 2024. This segment's leadership position is attributed to its widespread use in enhancing the visibility of vascular structures and organs during radiographic procedures. The segment's growth is driven by its essential role in CT imaging and angiography procedures, particularly in diagnosing cardiovascular conditions and cancer. Modern iodinated medical contrast agents are developed through chemical modifications of the 2,4,6 tri-iodinated benzene ring, offering improved safety profiles and imaging characteristics. The segment's robust performance is further supported by increasing adoption in emergency medicine, interventional radiology, and routine diagnostic imaging procedures across healthcare facilities worldwide.
Remaining Segments in Contrast Media Market
The contrast media market encompasses several other significant segments including gadolinium-based, microbubble, and barium-based contrast agents. Gadolinium-based radiological contrast agents play a crucial role in magnetic resonance imaging (MRI), offering enhanced visualization of blood vessels, tumors, inflammation, and blood supply in specific organs. Microbubble diagnostic contrast agents have carved out a niche in ultrasound imaging, particularly in echocardiography and vascular imaging applications. Barium-based radiological contrast agents continue to be the preferred choice for gastrointestinal tract imaging, providing superior mucosal detail and resistance to dilution compared to other contrast agents. Each of these segments serves specific imaging modalities and clinical applications, contributing to the overall diversity and effectiveness of diagnostic imaging procedures.
Global Diagnostic Radiopharmaceuticals and Contrast Media Market Geography Segment Analysis
Diagnostic Radiopharmaceuticals and Contrast Media Market in North America
North America represents a dominant force in the global radiopharmaceuticals market and contrast media market, driven by advanced healthcare infrastructure, high adoption of medical imaging technologies, and substantial investments in research and development. The region benefits from well-established reimbursement policies, an increasing prevalence of chronic diseases, and a growing geriatric population across the United States, Canada, and Mexico. The presence of major market players, coupled with continuous technological advancements in imaging modalities, further strengthens North America's market position in the global landscape.
Diagnostic Radiopharmaceuticals and Contrast Media Market in United States
The United States maintains its position as the largest market in North America, commanding approximately 85% of the regional market share. The country's market leadership is attributed to its robust healthcare system, extensive network of diagnostic centers, and significant investments in nuclear medicine facilities. The high prevalence of cardiovascular diseases and cancers, combined with increasing adoption of advanced imaging technologies, drives market growth. The presence of leading research institutions and continuous technological innovations in the diagnostic imaging market further reinforces the United States' dominant position in the market.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Canada
Canada emerges as the fastest-growing market in North America, with a projected growth rate of approximately 6% during 2024-2029. The country's market growth is fueled by increasing government initiatives in healthcare infrastructure development and rising investments in nuclear medicine facilities. Canada's focus on research and development in the radiopharmaceuticals market, coupled with growing awareness about early disease diagnosis, contributes to market expansion. The country's healthcare system's emphasis on preventive care and diagnostic imaging services further supports market growth.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Europe
Europe represents a significant market for the diagnostic imaging industry, characterized by advanced healthcare systems and strong research capabilities across Germany, the United Kingdom, France, Italy, and Spain. The region benefits from well-established regulatory frameworks, increasing investments in healthcare infrastructure, and growing adoption of advanced imaging technologies. The presence of major pharmaceutical companies and research institutions, coupled with rising awareness about early disease detection, continues to drive market growth across European countries.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Germany
Germany leads the European market, holding approximately 20% of the regional market share. The country's dominant position is supported by its advanced healthcare infrastructure, high healthcare spending, and strong presence of medical imaging equipment manufacturers. Germany's focus on technological innovation, coupled with an increasing prevalence of chronic diseases and a growing elderly population, drives market growth. The country's robust research and development activities in the nuclear medicine market further strengthen its market leadership.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Germany
Germany also demonstrates the highest growth potential in Europe, with an expected growth rate of approximately 6% during 2024-2029. The country's market expansion is driven by increasing investments in nuclear medicine facilities and growing adoption of hybrid imaging technologies. Germany's strong focus on research and development in the radiopharmaceuticals market, combined with rising demand for precise diagnostic imaging, supports market growth. The country's commitment to healthcare innovation and increasing applications of nuclear medicine continue to drive market expansion.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Asia-Pacific
The Asia-Pacific region demonstrates significant growth potential in the contrast media market, encompassing diverse healthcare markets across China, Japan, India, South Korea, and Australia. The region benefits from rapid healthcare infrastructure development, increasing healthcare expenditure, and growing awareness about early disease detection. Rising prevalence of chronic diseases, coupled with improving access to advanced medical imaging technologies, drives market growth across Asian countries.
Diagnostic Radiopharmaceuticals and Contrast Media Market in China
China emerges as the largest market in the Asia-Pacific region, driven by its extensive healthcare reforms and significant investments in medical imaging infrastructure. The country's large patient population, coupled with increasing healthcare expenditure and growing adoption of advanced diagnostic technologies, strengthens its market position. China's focus on expanding access to nuclear medicine facilities and growing awareness about early disease detection continues to drive market growth.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Japan
Japan demonstrates the highest growth potential in the Asia-Pacific region, supported by its advanced healthcare system and strong focus on technological innovation. The country's aging population, coupled with high adoption rates of advanced medical imaging technologies, drives market expansion. Japan's robust research and development activities in radiopharmaceuticals, combined with increasing applications in oncology and cardiology, contribute to market growth.
Diagnostic Radiopharmaceuticals and Contrast Media Market in Middle East and Africa
The Middle East and Africa region presents growing opportunities in the diagnostic radiopharmaceuticals and contrast media market, with significant contributions from GCC countries and South Africa. The region is experiencing increasing investments in healthcare infrastructure, rising awareness about early disease detection, and growing adoption of advanced medical imaging technologies. Among the countries, GCC emerges as the largest market while South Africa shows the fastest growth potential, driven by improving healthcare facilities and increasing focus on nuclear medicine applications.
Diagnostic Radiopharmaceuticals and Contrast Media Market in South America
South America demonstrates steady growth in the diagnostic radiopharmaceuticals and contrast media market, with Brazil and Argentina as key contributing countries. The region's market is characterized by increasing healthcare expenditure, growing awareness about early disease detection, and rising investments in medical imaging infrastructure. Brazil emerges as both the largest and fastest-growing market in the region, supported by its extensive healthcare network and increasing adoption of advanced diagnostic technologies.
Get Analysis on Important Geographic Markets
Download PDF
Diagnostic Radiopharmaceuticals and Contrast Media Industry Overview
Top Companies in Diagnostic Radiopharmaceuticals and Contrast Media Market
The leading companies in this market demonstrate a strong commitment to innovation through substantial R&D investments and continuous product development initiatives. These organizations are increasingly focusing on strategic collaborations and partnerships to enhance their product portfolios and expand their geographical reach. Many companies are pursuing vertical integration strategies, particularly in radiopharmaceuticals manufacturing and distribution networks. The industry leaders are also emphasizing technological advancement in diagnostic imaging solutions, with growing investment in AI-enabled platforms and automated radiology workflows. Companies are actively expanding their nuclear pharmacy networks and manufacturing facilities while simultaneously strengthening their supply chain capabilities to ensure reliable product availability. Additionally, there is a notable trend toward developing specialized contrast media agents and radiopharmaceuticals for specific diagnostic applications, particularly in oncology and cardiovascular imaging.
Consolidated Market Led By Global Players
The diagnostic radiopharmaceuticals and contrast media market exhibits a moderately consolidated structure dominated by large multinational healthcare conglomerates with diverse product portfolios. These established players leverage their extensive research capabilities, global distribution networks, and strong financial positions to maintain market leadership. The market features a mix of pharmaceutical giants and specialized nuclear medicine companies, with the former holding significant market share due to their integrated operations and broad product offerings. Regional players maintain a presence in specific geographical areas through specialized product lines and local manufacturing facilities.
The industry has witnessed significant merger and acquisition activity, particularly involving smaller innovative companies being acquired by larger corporations seeking to expand their technological capabilities and market presence. Companies are increasingly pursuing strategic partnerships with research institutions and healthcare providers to strengthen their market position. The competitive landscape is characterized by high entry barriers due to substantial capital requirements, complex regulatory frameworks, and the need for specialized expertise in nuclear medicine manufacturing and handling.
Innovation and Integration Drive Market Success
Success in this market increasingly depends on companies' ability to develop innovative products while maintaining efficient production and distribution networks. Market leaders are strengthening their positions through vertical integration, from isotope production to radiopharmacy operations, while also investing in next-generation imaging technologies and medical imaging agents formulations. Companies are focusing on developing personalized diagnostic solutions and expanding their product portfolios to address specific medical conditions, particularly in oncology and cardiovascular applications. The ability to maintain strong relationships with healthcare providers and ensure reliable supply chains has become crucial for maintaining market share.
For new entrants and smaller players, success lies in identifying specialized market niches and developing innovative solutions for specific diagnostic applications. Companies must navigate complex regulatory requirements while building robust distribution networks and establishing strategic partnerships with larger industry players. The market's future will be shaped by technological advancements in imaging modalities, growing demand for personalized medicine, and increasing focus on early disease detection. Regulatory compliance and quality assurance remain critical factors, particularly given the sensitive nature of radiopharmaceuticals products and their applications in diagnostic imaging.
Diagnostic Radiopharmaceuticals and Contrast Media Market Leaders
-
Cardinal Health Inc.
-
Siemens Healthineers
-
Bracco Imaging SpA
-
GE Company (GE Healthcare)
-
Guerbet Group
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Diagnostic Radiopharmaceuticals and Contrast Media Market News
In January 2021, QSAM Biosciences Inc. revealed its favorable safety results from the study to evaluate the radioactive impurity levels in its flagship drug candidate, Samarium-153-DOTMP (aka CycloSam).
In May 2020, the United States Food and Drug Administration (FDA) approved the radiopharmaceutical, flortaucipir F18 of Avid Radiopharmaceuticals, which is indicated to help image a distinctive characteristic of Alzheimer's disease.
Diagnostic Radiopharmaceuticals and Contrast Media Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Technology Advancements in Medical Imaging
- 4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
- 4.2.3 High Prevalence of Cancers and Cardiac Diseases
-
4.3 Market Restraints
- 4.3.1 High Costs of the Techniques
- 4.3.2 Limited Health Insurance Coverage
- 4.3.3 Short Half-life of Radiopharmaceuticals
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Radiopharmaceuticals
- 5.1.1 By Type of Imaging Modality
- 5.1.1.1 SPECT
- 5.1.1.1.1 Tc-99
- 5.1.1.1.2 Tl-201
- 5.1.1.1.3 Ga-67
- 5.1.1.1.4 I-123
- 5.1.1.1.5 Other SPECTs
- 5.1.1.2 PET
- 5.1.1.2.1 F-18
- 5.1.1.2.2 Rb-82
- 5.1.1.2.3 Other PETs
- 5.1.2 By Application
- 5.1.2.1 Diagnostic Application
- 5.1.2.1.1 SPECT Applications
- 5.1.2.1.1.1 Cardiology
- 5.1.2.1.1.2 Neurology
- 5.1.2.1.1.3 Thyroid
- 5.1.2.1.1.4 Other SPECT Applications
- 5.1.2.1.2 PET Application
- 5.1.2.1.2.1 Oncology
- 5.1.2.1.2.2 Cardiology
- 5.1.2.1.2.3 Neurology
- 5.1.2.1.2.4 Other PET Applications
- 5.1.2.2 Therapeutic Application
- 5.1.2.2.1 Thyroid
- 5.1.2.2.2 Lymphoma
- 5.1.2.2.3 Endocrine Tumors
- 5.1.2.2.4 Other Therapeutic Applications
-
5.2 Contrast Media
- 5.2.1 By Type
- 5.2.1.1 Iodinated Contrast Media
- 5.2.1.2 Gadolinium-based Contrast Media
- 5.2.1.3 Microbubble Contrast Media
- 5.2.1.4 Barium-based Contrast Media
- 5.2.2 By Procedure
- 5.2.2.1 X-ray/Computed Tomography (CT)
- 5.2.2.2 Magnetic Resonance Imaging (MRI)
- 5.2.2.3 Ultrasound
- 5.2.3 By Application
- 5.2.3.1 Cardiovascular Disease
- 5.2.3.2 Oncology
- 5.2.3.3 Gastrointestinal Disorders
- 5.2.3.4 Neurological Disorders
- 5.2.3.5 Other Indications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 United Kingdom
- 5.3.2.2 Germany
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 NTP Radioisotopes SOC Ltd
- 6.1.2 Bayer AG
- 6.1.3 Bracco Imaging SpA
- 6.1.4 Curium Pharma
- 6.1.5 GE Company (GE Healthcare)
- 6.1.6 Guerbet Group
- 6.1.7 Lantheus Holdings Inc.
- 6.1.8 Cardinal Health Inc.
- 6.1.9 Nano Therapeutics Pvt Ltd
- 6.1.10 Siemens Healthineers
- 6.1.11 Trivitron Healthcare
- 6.1.12 Koninklijke Philips NV
- 6.1.13 Triad Isotopes
- 6.1.14 Spago Nanomedical AB
- 6.1.15 Otsuka Pharmaceuticals Co. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now
Diagnostic Radiopharmaceuticals and Contrast Media Industry Segmentation
Radiopharmaceuticals are a group of pharmaceutical drugs that have radioactivity and can be used as diagnostics and therapeutic agents. Contrast media is the substance used to enhance the contrast of an image, hence, making an image more detailed and apparent. Contrast media is increasingly being used in various medical imaging techniques, such as MRI and CT. This report analyzes and discusses the global radiopharmaceuticals and contrast media market. The diagnostic radiopharmaceuticals and contrast media market is segmented by radiopharmaceuticals (by radiopharmaceuticals (by type of imaging modality (SPECT (Tc-99, Tl-201, Ga-67, I-123, and other SPECTs), PET (F-18, Rb-82, and other PETs), and application (diagnostic application (SPECT applications (cardiology, neurology, thyroid, and other SPECT applications) and PET application (oncology, cardiology, neurology, and other pet applications)), therapeutic application (thyroid, lymphoma, endocrine tumors, and other therapeutic applications), contrast media (type (iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media), procedure (X-ray/computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound) and applications (cardiovascular disease, oncology, gastrointestinal disorders, neurological disorders, and other indications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.
| Radiopharmaceuticals | By Type of Imaging Modality | SPECT | Tc-99 | ||
| Tl-201 | |||||
| Ga-67 | |||||
| I-123 | |||||
| Other SPECTs | |||||
| PET | F-18 | ||||
| Rb-82 | |||||
| Other PETs | |||||
| By Application | Diagnostic Application | SPECT Applications | Cardiology | ||
| Neurology | |||||
| Thyroid | |||||
| Other SPECT Applications | |||||
| PET Application | Oncology | ||||
| Cardiology | |||||
| Neurology | |||||
| Other PET Applications | |||||
| Therapeutic Application | Thyroid | ||||
| Lymphoma | |||||
| Endocrine Tumors | |||||
| Other Therapeutic Applications | |||||
| Contrast Media | By Type | Iodinated Contrast Media | |||
| Gadolinium-based Contrast Media | |||||
| Microbubble Contrast Media | |||||
| Barium-based Contrast Media | |||||
| By Procedure | X-ray/Computed Tomography (CT) | ||||
| Magnetic Resonance Imaging (MRI) | |||||
| Ultrasound | |||||
| By Application | Cardiovascular Disease | ||||
| Oncology | |||||
| Gastrointestinal Disorders | |||||
| Neurological Disorders | |||||
| Other Indications | |||||
| Geography | North America | United States | |||
| Canada | |||||
| Mexico | |||||
| Europe | United Kingdom | ||||
| Germany | |||||
| France | |||||
| Italy | |||||
| Spain | |||||
| Rest of Europe | |||||
| Asia-Pacific | China | ||||
| Japan | |||||
| India | |||||
| Australia | |||||
| South Korea | |||||
| Rest of Asia-Pacific | |||||
| Middle-East and Africa | GCC | ||||
| South Africa | |||||
| Rest of Middle-East and Africa | |||||
| South America | Brazil | ||||
| Argentina | |||||
| Rest of South America | |||||
Need A Different Region or Segment?
Customize Now
Diagnostic Radiopharmaceuticals and Contrast Media Market Research FAQs
How big is the Global Diagnostic Radiopharmaceuticals and Contrast Media Market?
The Global Diagnostic Radiopharmaceuticals and Contrast Media Market size is expected to reach USD 10.00 billion in 2025 and grow at a CAGR of 6.81% to reach USD 13.90 billion by 2030.
What is the current Global Diagnostic Radiopharmaceuticals and Contrast Media Market size?
In 2025, the Global Diagnostic Radiopharmaceuticals and Contrast Media Market size is expected to reach USD 10.00 billion.
Who are the key players in Global Diagnostic Radiopharmaceuticals and Contrast Media Market?
Cardinal Health Inc., Siemens Healthineers, Bracco Imaging SpA, GE Company (GE Healthcare) and Guerbet Group are the major companies operating in the Global Diagnostic Radiopharmaceuticals and Contrast Media Market.
Which is the fastest growing region in Global Diagnostic Radiopharmaceuticals and Contrast Media Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Diagnostic Radiopharmaceuticals and Contrast Media Market?
In 2025, the North America accounts for the largest market share in Global Diagnostic Radiopharmaceuticals and Contrast Media Market.
What years does this Global Diagnostic Radiopharmaceuticals and Contrast Media Market cover, and what was the market size in 2024?
In 2024, the Global Diagnostic Radiopharmaceuticals and Contrast Media Market size was estimated at USD 9.32 billion. The report covers the Global Diagnostic Radiopharmaceuticals and Contrast Media Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Diagnostic Radiopharmaceuticals and Contrast Media Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Diagnostic Radiopharmaceuticals and Contrast Media Market Research
Mordor Intelligence provides a comprehensive analysis of the nuclear medicine and diagnostic imaging industries. We leverage decades of expertise in healthcare market research. Our detailed report covers the evolving landscape of radiopharmaceuticals and contrast media. It offers crucial insights into molecular imaging agents and diagnostic imaging agents. Available as an easy-to-download report PDF, our analysis encompasses the complete spectrum of medical imaging contrast and radiological contrast agents. This offers stakeholders a thorough understanding of the diagnostic nuclear medicine sector.
The report equips industry participants with actionable intelligence on the radiopharmaceuticals market and contrast media market. It supports strategic decision-making across the nuclear medicine industry. Our extensive coverage includes a detailed analysis of medical contrast agents and diagnostic contrast agents. We also examine emerging trends in the diagnostic imaging industry. Stakeholders gain valuable insights into medical imaging agents applications, technological advancements, and regulatory frameworks. This report is an essential tool for understanding the dynamic diagnostic imaging market landscape.
